Vaccines to Treat Cancer Possible by 2030, Say BioNTech Founders
And though they partnered with Pfizer to ues the same approach for their Covid vaccine, “Now the doctors are hopeful it could lead to new treatments for melanoma, bowel cancer and other tumour types.”
BioNTech has several trials in progress, including one where patients are given a personalised vaccine, to prompt their immune system to attack their disease. The mRNA technology being used works by sending an instruction or blueprint to cells to produce an antigen or protein. In Covid this antigen is part of the spike protein of the virus. In cancer it would be a marker on the surface of tumour cells. This teaches the immune system to recognise and target affected cells for destruction.
Speaking on the BBC’s Sunday with Laura Kuenssberg, Prof Tureci said: “mRNA acts as a blueprint and allows you to tell the body to produce the drug or the vaccine… and when you use mRNA as a vaccine, the mRNA is a blueprint for the ‘wanted poster’ of the enemy — in this case cancer antigens which distinguish cancer cells from normal cells.”
Harnessing the power of mRNA to produce vaccines was unproven until Covid. But the success of mRNA vaccines in the pandemic has encouraged scientists working with the technology in cancer.
The Guardian notes that the couple said cancer-targetting vaccines could be available “before 2030”, though Özlem Türeci warns that “As scientists we are always hesitant to say we will have a cure for cancer. We have a number of breakthroughs and we will continue to work on them.”
BioNTech was working on mRNA cancer vaccines before the pandemic struck but the firm pivoted to produce Covid vaccines in the face of the global emergency. The firm now has several cancer vaccines in clinical trials.
Read more of this story at Slashdot.